@phdthesis{oai:niigata-u.repo.nii.ac.jp:02000464,
 author = {Suzuki, Hiroshi and 鈴木, 浩史},
 month = {2022-05-10, 2022-05-10},
 note = {Non-alcoholic steatohepatitis (NASH) is becoming the most common cause of hepatocellular carcinoma (HCC) in developed countries. Oxidative stress plays a major role in the pathogenesis of NASH due to steatosis and, hence, novel therapeutic approaches might include natural antioxidants. Ceraceomyces tessulatus (strain BDM-X), a novel edible mushroom, possesses potent antioxidant activity. This study aimed to investigate the hepatoprotective effect of BDM-X in a novel NASH-HCC mouse model. To prepare this animal model, 2-day-old C57BL/6J male pups were exposed to low-dose streptozotocin (STZ), and at 4 weeks of age they were randomly divided into 2 groups: the NASH group (NASH) received a high-fat diet (HFD32) up to 14 weeks of age; the BDM-X group (BDM-X) received HFD32 up to age 10 weeks, followed by HFD32 + 20% BDM-X (percentage W/W in the diet) up to age 14 weeks. Mice not treated with STZ fed a normal diet served as a control group. We found that BDM-X improved serum aminotransferase levels as well as histopathological features such as steatosis, inflammatory foci, and pericellular fibrosis in NASH mice. Hepatic protein expression of SREBP-1 and PPARα was significantly increased in NASH mice. BDM-X treatment normalized the expression of both proteins. Our data suggest the BDM-X may protect the liver against lipogenesis in NASH-HCC mice., International journal of medicinal mushrooms. 2022, 24(1), 41-52., 新大院博(医)第1022号},
 school = {新潟大学, Niigata University},
 title = {Meal ingestion Ceraceomyces tessulatus (Agaricomycetes) protects against NASH in mice},
 year = {}
}